Skip to main content

Chronic Kidney Disease with LDL Greater than or equal to 130 – Use of Lipid Lowering Agent

CBE ID
0627
Endorsement Status
1.1 New or Maintenance
Previous Endorsement Cycle
Is Under Review
No
1.3 Measure Description

The percentage of patients with chronic kidney disease stage 5 and an LDL greater than or equal to 130 mg/dl that have a current refill for a lipid lowering agent.

        • 1.14 Numerator

          Patients with a current refill for a lipid lowering agent.

        • 1.15 Denominator

          All patients, ages 18 and older, diagnosed with chronic kidney disease stage 5, dialysis, or kidney transplant, and an LDL level above 130 mg/dL.

        • Exclusions

          Specific Exclusions:
          None
          General Exclusions:
          • Evidence of metastatic disease or active treatment of malignancy (chemotherapy or radiation therapy) in the last 6 months;
          • Patients who have been in a skilled nursing facility in the last 3 months
          • Patient or provider feedback indicating allergy or intolerance to the drug in the past
          • Patient or provider feedback indicating that there is a contraindication to adding the drug

        • Most Recent Endorsement Activity
          Measure Retired and Endorsement Removed Renal Consensus Standards Endorsement Maintenance 2011
          Initial Endorsement
          Last Updated
          Removal Date
        • Steward
          ActiveHealth Management
          Steward Organization POC Email
          Steward Organization Copyright

          This information, including any attachments hereto, is the sole, exclusive, proprietary and confidential property of ActiveHealth Management, Inc., and is for the exclusive use of The National Quality Forum. Any use, copying, disclosure, dissemination or distribution by anyone other than the National Quality Forum is strictly prohibited.